Skip directly to search
Skip directly to A to Z list
Skip directly to navigation
Skip directly to page options
Skip directly to site content
Start of Search Controls
Search Form Controls
Search The CDC
submit
CDC A-Z Index
MENU
CDC A-Z
SEARCH
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Search Form Controls
Search The CDC
submit
CDC A-Z Index
Public Health Genomics Knowledge Base (v5.3)
Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page:
About CDC.gov
.
PHGKB
About
MyPHGKB
Specialized PHGKB
Cancer PHGKB
Infectious Diseases PHGKB
HLBS-PopOmics
Genomics (A-Z)
Office of Public Health Genomics
My Family Health Portrait
State Public Health Genomics Programs Map
Genomics & Health Impact Weekly Scan
(Current Edition)
Advanced Molecular Detection Weekly Clips
(Current Edition)
All Databases
CDC/NIH Web Information Database (7887)
CDC-Authored Genomics Publications Database (2221)
Genomics & Health Impact Scan Database (19072)
Tier Table Database (180)
State Public Health Genomics Programs Database (275)
Advanced Molecular Detection Clips Database (10506)
GRANTOMICS (54076)
HuGE Navigator
Phenopedia (3152)
Genopedia (15137)
HuGE Literature Finder (140139)
Variant Name Mapper (18583)
DataSet Download Center
Release Note
Contact Us
Tier Table Database
Please WaitÂ
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Tier Table Database|Search|PHGKB
Last data update: Dec 21, 2018
. (Total: 180 Documents)
Filtered By:
Select to fine-tune your search
Tier
Disease
Gene
Basis
Records 1-34 (
34 records found
)
Query Trace:
All HLBS[orginal query]
Disease/Disorder
Test or Application
Intended Use
Tier Classified
Detail
Cystic fibrosis (CF)
CFTR (detection of F508del homozygousity)
Pharmacogenomic for ivacaftor and lumacaftor combination
Tier 1
Hypertrophic cardiomyopathy (HCM) - symptoms and signs of disease suggesting specific causes of HCM
Genetic testing (including analysis of most frequently implicated sarcomere protein genes)
Confirm diagnosis of HCM
Tier 1
Hypertrophic cardiomyopathy (HCM)
Genetic testing (including analysis of most frequently implicated sarcomere protein genes)
Enable cascade screening of relatives
Tier 1
Hypertrophic cardiomyopathy (HCM) that cannot be explained solely by non-genetic cause
Genetic counseling
Help patients understand and manage HCM
Tier 1
Chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema
UGT1A1
Pharmacogenomic for indacaterol
Tier 2
Narcolepsy, obstructive sleep apnea, and shift work disorder
CYP2D6
Pharmacogenomic for modafinil, dose
Tier 2
Insomnia
CYP2D6, CYP2C19
Pharmacogenomic for doxepin, dose
Tier 2
Thrombocytopenia
F5, SERPINC1
Pharmacogenomic for eltrombopag
Tier 2
Hypercholesterolemia
LDLR
Pharmacogenomic for pravastatin
Tier 2
Acute coronary syndrome
CYP2C19
Pharmacogenomic for ticagrelor
Tier 2
Acute coronary syndrome managed with percutaneous coronary intervention
CYP2C19
Pharmacogenomic for prasugrel
Tier 2
Non-ST-segment elevation acute coronary syndrome, ST-elevation myocardial infarction, myocardial infarction, stroke, peripheral arterial disease
CYP2C19
Pharmacogenomic for clopidogrel
Tier 2
Atrial fibrillation
CYP2D6
Pharmacogenomic for propafenone
Tier 2
Chronic heart failure, left ventricular dysfunction following myocardial infarction, hypertension
CYP2D6
Pharmacogenomic for carvedilol
Tier 2
Hypertension, angina pectoris, heart failure
CYP2D6
Pharmacogenomic for metoprolol
Tier 2
Venous thrombosis, pulmonary embolism, thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement, myocardial infarction
CYP2C9, VKORC1
Pharmacogenomic for warfarin dose
Tier 2
Non–small cell lung cancer
KRAS mutations [except c38G>A]
Predictive; prognostic; for anti-EGFR therapy
Tier 2
Hypereosinophilic syndrome and/or chronic eosinophilic leukemia
FIP1L1-PDGFRA kinase
Pharmacogenomic for imatinib, dose
Tier 2
Philadelphia chromosome positive chronic myeloid leukemia
UGT1A1*28 homozygotes
Pharmacogenomic for nilotinib
Tier 2
Chronic myelogenous leukemia
Philadelphia chromosome
Pharmacogenomic for busulfan
Tier 2
Cystic fibrosis (CF)
CFTR mutation analysis
Pharmacogenomic for ivacaftor
Tier 1
Lipid disorders, cholesterol, dyslipidemia
Family history of cardiovascular disease before age 50 years in male relatives and age 60 years in female relatives
Risk factor (for coronary heart disease) to inform cholesterol screening
Tier 1
Familial hypercholesterolemia (FH)
DNA testing and LDL-C concentration measurement
Cascade testing of relatives of people diagnosed with FH
Tier 1
Non-small cell lung cancer
ALK gene rearrangement
Pharmacogenomic for crizotinib
Tier 1
Locally advanced or metastatic non-small-cell lung cancer
EGFR (exon 19 deletions and exon 21 (L858R) substitution mutations)
Pharmacogenomic for erlotinib
Tier 1
Metastatic non-small-cell lung cancer
EGFR (exon 19 deletions and exon 21 (L858R) substitution mutations)
Pharmacogenomic for afatinib
Tier 1
Transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q
Chromosome 5q deletion
Pharmacogenomic for lenalidomide
Tier 1
Myelodysplastic/myeloproliferative diseases
PDGFRB
Pharmacogenomic for imatinib
Tier 1
Chronic myeloid leukemia
Philadelphia chromosome
Pharmacogenomic for nilotinib; diagnostic
Tier 1
Chronic myelogenous leukemia
Philadelphia chromosome
Pharmacogenomic for bosutinib; diagnostic
Tier 1
Chronic myeloid leukemia, acute lymphoblastic leukemia
Philadelphia chromosome
Pharmacogenomic for imatinib; diagnostic
Tier 1
Chronic myeloid leukemia, acute lymphoblastic leukemia
Philadelphia chromosome, T315I mutation
Pharmacogenomic for dasatinib; diagnostic
Tier 1
File Formats Help:
How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?
Adobe PDF file
Microsoft PowerPoint file
Microsoft Word file
Microsoft Excel file
Audio/Video file
Apple Quicktime file
RealPlayer file
Text file
Zip Archive file
SAS file
ePub file
Page last reviewed:
Mar 1, 2018
Page last updated:
Dec 21, 2018
Content source:
Office of Public Health Genomics
,
Center for Surveillance, Epidemiology and Laboratory Services (CSELS)
TOP